These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24502970)

  • 1. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
    Lund-Andersen C; Patzke S; Nähse-Kumpf V; Syljuåsen RG
    Radiother Oncol; 2014 Feb; 110(2):355-61. PubMed ID: 24502970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
    Jemaà M; Kifagi C; Serrano SS; Massoumi R
    Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
    Bogado RF; Pezuk JA; de Oliveira HF; Tone LG; Brassesco MS
    Anticancer Drugs; 2015 Jan; 26(1):56-63. PubMed ID: 25089571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation.
    Krause M; Kummer B; Deparade A; Eicheler W; Pfitzmann D; Yaromina A; Kunz-Schughart LA; Baumann M
    Radiother Oncol; 2013 Sep; 108(3):422-8. PubMed ID: 23891096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
    Brassesco MS; Pezuk JA; Salomão KB; Roberto GM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2018; 18(9):1252-1257. PubMed ID: 29493466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
    Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
    Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
    Yao D; Gu P; Wang Y; Luo W; Chi H; Ge J; Qian Y
    Biochem Cell Biol; 2018 Jun; 96(3):317-325. PubMed ID: 29040814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
    Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
    Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLK1 Inhibition Sensitizes Breast Cancer Cells to Radiation via Suppressing Autophagy.
    Wang B; Huang X; Liang H; Yang H; Guo Z; Ai M; Zhang J; Khan M; Tian Y; Sun Q; Mao Z; Zheng R; Yuan Y
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1234-1247. PubMed ID: 33621661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
    Wu M; Wang Y; Yang D; Gong Y; Rao F; Liu R; Danna Y; Li J; Fan J; Chen J; Zhang W; Zhan Q
    EBioMedicine; 2019 Mar; 41():244-255. PubMed ID: 30876762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.